Provides an important new functionality for formulation and manufacturing personnel who need to understand the impact of humidity on their products
UK-based Gamlen Tableting has launched an addition to its tablet press product range, the GTP-CHE system, which offers a unique solution to users wishing to study the effect of humidity on tablet compaction behaviour.
The GTP-CHE consists of a Gamlen Tablet Press (GTP) operating within a controlled humidity environment (CHE). Operating between 10 and 90% humidity, the system uses a proprietary humidity generator combined with a glove box system which holds the GTP.
As with all GTP models, operation requires only a few simple steps; samples are equilibrated in the controlled environment, weighed, compacted using the GTP-1 in compaction mode, and then tested in the GTP-1 fracture mode to determine tablet fracture stress.
The system will be launched at AAPS 2013, the annual meeting of the American Association of Pharmaceutical Scientists to be held in San Antonio, Texas from 9-14 November 2013.
The new GTP-CHE builds on the versatility of the GTP-1. Entirely computer controlled, the Gamlen Tablet Press is a portable laboratory machine that can be used for material characterisation, pre-formulation, formulation and process development, QbD for tablets and QC of incoming APIs and excipients. Data generated on the machine can be directly translated to the production situation.
'The GTP-CHE model provides a unique and important new functionality for formulation and manufacturing personnel who need to understand the impact of humidity on their formulations and products,' said Managing Director Michael Gamlen.
'The behaviour of many important pharmaceutical materials is humidity-dependent in the normal operating ranges used by the industry. Our new capability will help people to understand these effects in order to tackle or avoid problems in an objective way. I truly believe that the Gamlen Tablet Press can improve the quality control of tableted products.'
Gamlen Tablet Presses have been purchased by UK and international bodies including Actavis UK, De Montfort University, GlaxoSmithKline, Jordanian Pharmaceutical Company, MIT USA, Monash University Australia and Reckitt Benckiser UK.